ReviewCardiovascular research2021
Cardiovascular consequences of viral infections: from COVID to other viral diseases.
Review in Cardiovascular research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2025Pooled it
- Trial
- Causal associations between antibody-mediated immune responses to infectious agents and cardiovascular inflammatory diseases: A Mendelian randomization study based on UK Biobank and FinnGen.Human vaccines & immunotherapeutics · 2026Article
- Cardiovascular and mortality risks following COVID-19-related versus non-COVID-19-related chronic obstructive pulmonary disease exacerbations.Annals of the American Thoracic Society · 2026Article
- COVID-19 Vaccination in Heart Failure: Evidence From Nationwide Data.Korean circulation journal · 2026Article
- From infection to intervention: post-acute sequelae of SARS-CoV-2 infection and cardiovascular risk.Inflammopharmacology · 2025Review
- Vaccination in Patients with Cardiovascular Disease: A Case-Based Approach and Contemporary Review.CJC open · 2025Review
- Article
- Discovery of miRNAs unique to actively transcribed erythroparvovirus infection in heart failure patients.ESC heart failure · 2025Article
- Genetic and Epigenetic Intersections in COVID-19-Associated Cardiovascular Disease: Emerging Insights and Future Directions.Biomedicines · 2025Review
- Innate Immune Dysregulations and Cross Talk in COVID-19: Novel Players in Atherogenesis.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Integrative Bioinformatics Approaches to Uncover Hub Genes and Pathways Involved in Cardiovascular Diseases.Cell biochemistry and biophysics · 2024Article
- New insights gained from cellular landscape changes in myocarditis and inflammatory cardiomyopathy.Heart failure reviews · 2024Review
- Elevated Cardiac Troponin I as a Mortality Predictor in Hospitalised COVID-19 Patients.Medicina (Kaunas, Lithuania) · 2024Observational
- Viral cardiovascular surgical diseases: global burdens, challenges and opportunities.Future cardiology · 2024Review
- Review
- Review
- Advancing Precision Medicine in Myocarditis: Current Status and Future Perspectives in Endomyocardial Biopsy-Based Diagnostics and Therapeutic Approaches.Journal of clinical medicine · 2023Review
- Article
- Bulk and single-cell characterisation of the immune heterogeneity of atherosclerosis identifies novel targets for immunotherapy.BMC biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Infection of the heart muscle with cardiotropic viruses is one of the major aetiologies of myocarditis and acute and chronic inflammatory cardiomyopathy (DCMi). However, viral myocarditis and subsequent dilated cardiomyopathy is still a challenging disease to diagnose and to treat and is therefore a significant public health issue globally. Advances in clinical examination and thorough molecular genetic analysis of intramyocardial viruses and their activation status have incrementally improved our understanding of molecular pathogenesis and pathophysiology of viral infections of the heart muscle. To date, several cardiotropic viruses have been implicated as causes of myocarditis and DCMi. These include, among others, classical cardiotropic enteroviruses (Coxsackieviruses B), the most commonly detected parvovirus B19, and human herpes virus 6. A newcomer is the respiratory virus that has triggered the worst pandemic in a century, SARS-CoV-2, whose involvement and impact in viral cardiovascular disease is under scrutiny. Despite extensive research into the pathomechanisms of viral infections of the cardiovascular system, our knowledge regarding their treatment and management is still incomplete. Accordingly, in this review, we aim to explore and summarize the current knowledge and available evidence on viral infections of the heart. We focus on diagnostics, clinical relevance and cardiovascular consequences, pathophysiology, and current and novel treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.